Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Guldbrandsen A, Farag Y, Kroksveen AC, Oveland E, Lereim RR, Opsahl JA, Myhr KM, Berven FS, Barsnes H.

Mol Cell Proteomics. 2017 Feb;16(2):300-309. doi: 10.1074/mcp.O116.064477. Epub 2016 Nov 27.

2.

Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.

Opsahl JA, Vaudel M, Guldbrandsen A, Aasebø E, Van Pesch V, Franciotta D, Myhr KM, Barsnes H, Berle M, Torkildsen Ø, Kroksveen AC, Berven FS.

Proteomics. 2016 Apr;16(7):1154-65. doi: 10.1002/pmic.201500284.

PMID:
26841090
3.

Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.

Kroksveen AC, Jaffe JD, Aasebø E, Barsnes H, Bjørlykke Y, Franciotta D, Keshishian H, Myhr KM, Opsahl JA, van Pesch V, Teunissen CE, Torkildsen Ø, Ulvik RJ, Vethe H, Carr SA, Berven FS.

Proteomics. 2015 Oct;15(19):3361-9. doi: 10.1002/pmic.201400142. Epub 2015 Sep 8.

PMID:
26152395
4.

Cerebrospinal fluid proteomics in multiple sclerosis.

Kroksveen AC, Opsahl JA, Guldbrandsen A, Myhr KM, Oveland E, Torkildsen Ø, Berven FS.

Biochim Biophys Acta. 2015 Jul;1854(7):746-56. doi: 10.1016/j.bbapap.2014.12.013. Epub 2014 Dec 16. Review.

PMID:
25526888
5.

In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR).

Guldbrandsen A, Vethe H, Farag Y, Oveland E, Garberg H, Berle M, Myhr KM, Opsahl JA, Barsnes H, Berven FS.

Mol Cell Proteomics. 2014 Nov;13(11):3152-63. doi: 10.1074/mcp.M114.038554. Epub 2014 Jul 18.

6.

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.

Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT.

Mol Cancer. 2014 May 21;13:116. doi: 10.1186/1476-4598-13-116.

7.

Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome.

Aasebø E, Opsahl JA, Bjørlykke Y, Myhr KM, Kroksveen AC, Berven FS.

PLoS One. 2014 Mar 5;9(3):e90429. doi: 10.1371/journal.pone.0090429. eCollection 2014.

8.

Identification of dynamic changes in proteins associated with the cellular cytoskeleton after exposure to okadaic acid.

Opsahl JA, Ljostveit S, Solstad T, Risa K, Roepstorff P, Fladmark KE.

Mar Drugs. 2013 May 24;11(6):1763-82. doi: 10.3390/md11061763.

9.

Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.

Kroksveen AC, Guldbrandsen A, Vedeler C, Myhr KM, Opsahl JA, Berven FS.

Acta Neurol Scand Suppl. 2012;(195):90-6. doi: 10.1111/ane.12029.

PMID:
23278663
10.

Protein profiling reveals inter-individual protein homogeneity of arachnoid cyst fluid and high qualitative similarity to cerebrospinal fluid.

Berle M, Kroksveen AC, Haaland OA, Aye TT, Opsahl JA, Oveland E, Wester K, Ulvik RJ, Helland CA, Berven FS.

Fluids Barriers CNS. 2011 May 20;8:19. doi: 10.1186/2045-8118-8-19.

11.

Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.

Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS.

J Proteomics. 2011 Apr 1;74(4):371-88. doi: 10.1016/j.jprot.2010.11.010. Epub 2010 Nov 25. Review.

PMID:
21111852
12.

Increased interaction between DJ-1 and the Mi-2/ nucleosome remodelling and deacetylase complex during cellular stress.

Opsahl JA, Hjørnevik LV, Bull VH, Fismen L, Frøyset AK, Gromyko D, Solstad T, Fladmark KE.

Proteomics. 2010 Apr;10(7):1494-504. doi: 10.1002/pmic.200900586.

PMID:
20127688
13.

Iodine concentration in Norwegian milk and dairy products.

Dahl L, Opsahl JA, Meltzer HM, Julshamn K.

Br J Nutr. 2003 Sep;90(3):679-85.

PMID:
13129475
14.

Myocardial enzymatic activity of renin and cathepsin D before and after bilateral nephrectomy.

Katz SA, Opsahl JA, Forbis LM.

Basic Res Cardiol. 2001 Nov;96(6):659-68.

PMID:
11770086
15.

Myocardial renin is neither necessary nor sufficient to initiate or maintain ventricular hypertrophy.

Katz SA, Opsahl JA, Wernsing SE, Forbis LM, Smith J, Heller LJ.

Am J Physiol Regul Integr Comp Physiol. 2000 Mar;278(3):R578-86.

16.

Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction.

Hirsch AT, Opsahl JA, Lunzer MM, Katz SA.

Am J Physiol. 1999 Jun;276(6):H1818-26. doi: 10.1152/ajpheart.1999.276.6.H1818.

PMID:
10362659
17.

Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy.

Heller LJ, Opsahl JA, Wernsing SE, Saxena R, Katz SA.

Am J Physiol. 1998 Mar;274(3):R849-56. doi: 10.1152/ajpregu.1998.274.3.R849.

PMID:
9530254
18.

Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium.

Katz SA, Opsahl JA, Lunzer MM, Forbis LM, Hirsch AT.

Hypertension. 1997 Aug;30(2 Pt 1):259-66.

PMID:
9260990
19.

Active renin and renin glycoform dynamics in the carotid artery.

Katz SA, Opsahl JA, Forbis LM, Ayenew W.

Am J Physiol. 1996 Jul;271(1 Pt 2):H184-91.

PMID:
8760174
20.

Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms.

Opsahl JA, Goldberg MR, Katz SA.

Am J Hypertens. 1995 Nov;8(11):1090-8.

PMID:
8554732
21.

Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease.

Awni WM, Halstenson CE, Nayak RK, Opsahl JA, Desiraju RK, Minn FL, Matzke GR.

J Clin Pharmacol. 1995 Apr;35(4):379-83.

PMID:
7650227
22.

A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients.

Rinehart AL, Herzog CA, Collins AJ, Flack JM, Ma JZ, Opsahl JA.

Am J Kidney Dis. 1995 Feb;25(2):281-90.

PMID:
7847356
23.

Effects of hemodialysis on plasma protein binding of bepridil.

Pritchard JF, Matzke GR, Opsahl JA, Halstenson CE, Nayak RK.

J Clin Pharmacol. 1995 Feb;35(2):137-41.

PMID:
7751422
24.

Urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in mild hypertension.

Abraham PA, Mascioli SR, Launer CA, Flack JM, Liebson PR, Svendsen KH, Grandits GA, Opsahl JA, Schoenberger JA, Grimm RH Jr.

Am J Hypertens. 1994 Nov;7(11):965-74.

PMID:
7848623
25.

The relationship between renin isoelectric forms and renin glycoforms.

Katz SA, Opsahl JA, Abraham PA, Gardner MJ.

Am J Physiol. 1994 Jul;267(1 Pt 2):R244-52.

PMID:
8048628
26.

Role of renin isoelectric heterogeneity in renal storage and secretion of renin.

Opsahl JA, Abraham PA, Shake JG, Katz SA.

J Am Soc Nephrol. 1993 Oct;4(4):1054-63.

27.

Renin and renin inhibition in anephric man.

Opsahl JA, Smith KL, Murray RD, Abraham PA, Katz SA.

Clin Exp Hypertens. 1993 Mar;15(2):289-306.

PMID:
8467318
28.

Measurement of human active renin heterogeneity.

Katz SA, Abraham PA, Opsahl JA.

Ren Physiol Biochem. 1992 Sep-Oct;15(5):240-8.

PMID:
1279764
29.

Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies.

Abraham PA, Halstenson CE, Macres MM, Opsahl JA, Rank BH, Schwenk MH, Lasky LC, Cohen A, Lasseter KC, Smith DL, et al.

Clin Pharmacol Ther. 1992 Aug;52(2):205-13.

PMID:
1380411
30.

Bioavailability of labetalol in patients with end-stage renal disease.

Luke DR, Awni WM, Halstenson CE, Opsahl JA, Matzke GR.

Ther Drug Monit. 1992 Jun;14(3):203-8.

PMID:
1412606
31.

The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function.

Halstenson CE, Opsahl JA, Rachael K, Olson SC, Horvath AM, Abraham PA, Posvar EL.

J Clin Pharmacol. 1992 Apr;32(4):344-50.

PMID:
1569237
32.

Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers.

Guay DR, Opsahl JA, McMahon FG, Vargas R, Matzke GR, Flor S.

Antimicrob Agents Chemother. 1992 Feb;36(2):308-12.

33.

Analysis of active renin heterogeneity.

Katz SA, Malvin RL, Lee J, Kim SH, Murray RD, Opsahl JA, Abraham PA.

Proc Soc Exp Biol Med. 1991 Sep;197(4):387-92.

PMID:
1908097
34.
35.

Acute stimulation of renin secretion changes the multiple form profile of active plasma renin.

Opsahl JA, Abraham PA, Katz SA.

Am J Hypertens. 1991 Feb;4(2 Pt 1):126-30.

PMID:
2021443
36.

A review of disorders of water homeostasis in psychiatric patients.

Riggs AT, Dysken MW, Kim SW, Opsahl JA.

Psychosomatics. 1991 Spring;32(2):133-48. Review.

PMID:
2027935
37.

Disposition of the cephalosporin cefepime in normal and renally impaired subjects.

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, Pittman KA.

Drug Metab Dispos. 1991 Jan-Feb;19(1):68-73.

PMID:
1673424
38.

Renal secretion and hepatic clearance of human multiple renin forms.

Abraham PA, Katz SA, Opsahl JA, Miller RP, Stanchfield WR Jr, Andersen RC.

Hypertension. 1990 Dec;16(6):669-76.

PMID:
2246033
39.

Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin.

Flor S, Guay DR, Opsahl JA, Tack K, Matzke GR.

Antimicrob Agents Chemother. 1990 Dec;34(12):2436-8.

40.

Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.

Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, McLain LA, Hanson G, Davis MG, Halstenson CE.

Am J Kidney Dis. 1990 Nov;16(5):438-46.

PMID:
2239934
41.

Validity of creatinine clearance estimates in the assessment of renal function.

Luke DR, Halstenson CE, Opsahl JA, Matzke GR.

Clin Pharmacol Ther. 1990 Nov;48(5):503-8.

PMID:
2225710
42.

Effect of acute stimulation of renin secretion on renal renin content in vivo.

Opsahl JA, Abraham PA, Katz SA.

Kidney Int. 1990 Sep;38(3):440-6.

43.

Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.

Halstenson CE, Guay DR, Opsahl JA, Hirata CA, Olanoff LS, Novak E, Ko H, Cathcart KS, Matzke GR.

Antimicrob Agents Chemother. 1990 Apr;34(4):519-23.

44.

Pharmacokinetics of loratadine in patients with renal insufficiency.

Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, Zampaglione N.

J Clin Pharmacol. 1990 Apr;30(4):364-71.

PMID:
2140371
45.

Disposition of roxithromycin in patients with normal and severely impaired renal function.

Halstenson CE, Opsahl JA, Schwenk MH, Kovarik JM, Puri SK, Ho I, Matzke GR.

Antimicrob Agents Chemother. 1990 Mar;34(3):385-9.

46.

Renal effects of angiotensin converting enzyme inhibitors: nondiabetic chronic renal disease.

Opsahl JA, Abraham PA, Keane WF.

Cardiovasc Drugs Ther. 1990 Feb;4(1):221-8.

PMID:
2285614
47.

Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.

Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE.

Am J Nephrol. 1990;10(2):128-36.

PMID:
2349956
48.

Angiotensin-converting enzyme inhibitors in chronic renal failure.

Opsahl JA, Abraham PA, Keane WF.

Drugs. 1990;39 Suppl 2:23-32. Review.

PMID:
2188823
49.

Effect of haemodialysis on the pharmacokinetics of cetirizine.

Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR.

Eur J Clin Pharmacol. 1990;38(1):67-9.

PMID:
1970299
50.

Antihypertensive and humoral effects of nifedipine in essential hypertension uncontrolled by hydrochlorothiazide alone.

Opsahl JA, Halstenson CE, Abraham PA.

Am J Hypertens. 1989 Nov;2(11 Pt 1):828-33.

PMID:
2686710

Supplemental Content

Loading ...
Support Center